Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 14/20 | 0.81 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280745 | 0.92 | SMO (0.83) | SMOHTTNPSR1MEN1KMT2A | |
| SCHEMBL2277847 | 0.90 | SMO (0.67) | SMOHTTNPSR1MEN1KMT2A | |
| SCHEMBL1091116 | 0.90 | SMO (1.00) | SMO | |
| SCHEMBL1091112 | 0.90 | SMO (1.00) | SMO | |
| SCHEMBL1091574 | 0.90 | SMO (1.00) | SMO | |
| SCHEMBL2276591 | 0.89 | SMO (0.66) | SMOHTTNPSR1KDR | |
| SCHEMBL2272806 | 0.89 | SMO (0.84) | SMOKDR | |
| SCHEMBL2216812 | 0.87 | SMO (0.62) | SMO | |
| SCHEMBL4166778 | 0.86 | SMO (0.70) | SMOHTTNPSR1MEN1KMT2A | |
| SCHEMBL1091208 | 0.86 | SMO (0.92) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364185-B1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8404687-B2 | Disubstituted phthalazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110190304-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190304-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, GLI1, SMO | SMO 3/4885HTT 1781/4885NPSR1 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.